Table of Contents
What changed
Revenue rose 14.6% to NZ$355.1m, with PBT up 20.1% to NZ$21.3m and parent NPAT up 17.6% to NZ$11.4m. Operating cash flow jumped 62.5% to NZ$28.9m, versus capex of just NZ$3.0m, lifting pre-lease free cash flow to NZ$25.8m from NZ$15.7m. Cash on hand increased to NZ$43.6m and gross borrowings edged down to NZ$24.8m, taking the group to a net cash position of about NZ$18.9m (prior: NZ$5.9m). Segment mix shifted: Pharmacy services' share of revenue fell ~3.9pp to 50.6% and its segment margin eased to ~6.5% from ~7.9%, while Medical services grew to 19.2% of revenue (margin up to ~13.6%) and Community Health segment profit roughly tripled to NZ$6.6m on a margin lift to ~6.2% from ~2.6%. An interim dividend of NZ$5.0m was declared, against nil at HY22.
What matters
- Pharmacy margin fade in the biggest segment. Pharmacy revenue grew only ~6.3% and segment profit actually fell (NZ$13.3m → NZ$11.6m). Group earnings growth is currently being carried by Community Health and Medical, not by the dominant division — a mix-driven outcome rather than a broad-based uplift.
- Cash quality is strong this half. OCF of NZ$28.9m comfortably exceeds NPAT (~227% conversion), receivable days improved to 17.2 from 19.4 and inventory days to 16.6 from 19.1. This is genuine operating strength, not a receivables drawdown masking weaker earnings.
- Tax drag, not operating weakness, is the NPAT story. The effective tax rate rose to 30.3% from 26.8%, widening the gap between 20.1% PBT growth and 17.6% NPAT growth. PBT is the cleaner read on underlying earnings momentum here.
Expectations
No target or forward-work figure is disclosed in the supplied material, and no formal guidance is identified. The shape context is informative, however: HY22 represented only 39.3% of FY22 NPAT and 46.2% of FY22 revenue, so GXH historically earns materially more in the second half. Simple annualisation of HY23 revenue gives NZ$710.2m, about 6.0% above FY22's NZ$670.3m, but if the usual second-half weighting holds, full-year revenue and earnings would print meaningfully higher than a doubling of HY23. The release supports a stronger FY23 shape than FY22; it does not, on its own, establish a new run-rate because pharmacy momentum is the swing factor for 2H.
Quality of result
The underlying quality looks reasonable rather than flattered. Earnings growth is supported — not manufactured — by working capital, with receivable and inventory days both shorter than a year ago and operating cash flow running well ahead of accounting profit. Capex at ~0.9% of revenue is low, which inflates FCF optically but is consistent with an asset-light pharmacy/services model. Two caveats: (i) group EBITDA is not disclosed in the supplied material, so cash-to-EBITDA conversion cannot be verified; and (ii) a large share of the PBT uplift is concentrated in Community Health, whose segment profit swung from NZ$2.5m to NZ$6.6m — durable if operationally driven, but the release excerpts do not explain the specific driver.
Unresolved
- What caused the Community Health margin to more than double, and is the HY23 level sustainable into 2H?
- Why did pharmacy segment profit fall despite revenue growth — cost inflation, mix, or specific regulatory/funding pressure?
- Why did the effective tax rate rise from 26.8% to 30.3%, and is 30%+ the right forward assumption?
- What is management's FY23 expectation, and is there any forward-work or contracted-revenue disclosure behind the Medical services step-up?
- How much of the net cash build reflects timing of payables (not disclosed) versus genuine operating accretion?
This briefing cannot assess valuation, management commentary tone, or any covenant, regulatory, or contract-renewal detail not contained in the supplied extraction.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $355.1m | $309.9m | +14.6% ↑ |
| Net profit after tax | $11.4m | $9.7m | +17.6% ↑ |
| Net cash inflow from operating activities | $28.9m | $17.8m | +62.5% ↑ |
| Operating profit | $24.7m | $20.5m | +20.6% ↑ |
| Profit before tax | $21.3m | $17.7m | +20.1% ↑ |
| Cash and cash equivalents | $43.6m | $32.2m | +35.5% ↑ |
| Total assets | $414.5m | $373.8m | +10.9% ↑ |
Reference: annolyse.ai/briefings/gxh-hy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Pharmacy services | $179.5m | $168.9m | $11.6m | -3.9pp |
| Medical services | $68.2m | $46.1m | $9.3m | +4.3pp |
| Community Health | $106.5m | $93.7m | $6.6m | -0.2pp |
Reference: annolyse.ai/briefings/gxh-hy23
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| PBT growth | +20.1% | — | cleaner earnings measure |
| Effective tax rate | 30.3% | 26.8% | — |
| FCF pre-lease | $25.8m | $15.7m | +$10.2m |
| FCF / NPAT | 227.5% | 162.2% | complementary conversion metric |
| Capex % revenue | 0.9% | 0.7% | — |
| Capex | −$3.0m | −$2.1m | −$0.9m |
| Debtor days | 17.2 | 19.4 | -2.2 days |
| Inventory days | 16.6 | 19.1 | -2.5 days |
| Trade debtors | $33.6m | $33.1m | +$0.5m |
| Net debt | −$18.9m | −$5.9m | −$13.0m |
| Gross borrowings | $24.8m | $26.3m | −$1.5m |
| Payout ratio vs NPAT | 44.3% | — | — |
| Payout ratio vs FCF pre-lease | 19.5% | — | covered |
| ROE (annualised) | 6.8% | 5.8% | Strengthening |
| HY22 share of FY22 revenue | 46.2% | — | Other half was 53.8% |
| HY22 share of FY22 NPAT | 39.3% | — | Other half was 60.7% |
Reference: annolyse.ai/briefings/gxh-hy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.